# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B. Riley Securities analyst Matt Howlett reiterates Abacus Life (NASDAQ:ABL) with a Buy and raises the price target from $15...
New partnership leverages PREADISAN™, the cutting-edge health prediction platform using machine learning and modern proteomics ...
Abacus Life (NASDAQ:ABL) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.12 by 5...
TD Cowen analyst Andrew Kilgerman initiates coverage on Abacus Life (NASDAQ:ABL) with a Buy rating and announces Price Targe...
Acquisition accelerates expansion of ABL Wealth with a diverse suite of products Deal will add up to $600 million in AUM to Aba...
The company expects Q2 net income between $0.0 and $1.0 million, Adjusted EBITDA between $15.0 and $17.0 million. Jay Jackson,...